Rockwell Medical (NASDAQ:RMTI) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Rockwell Medical (NASDAQ:RMTI) posted its quarterly earnings data on Monday. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01), Zacks reports. Rockwell Medical had a positive return on equity of 8.55% and a negative net margin of 1.25%. Rockwell Medical updated its FY 2025 guidance to EPS.

Rockwell Medical Stock Performance

Shares of RMTI opened at $1.12 on Monday. The company has a market capitalization of $38.11 million, a PE ratio of -22.30 and a beta of 1.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41. The company’s 50 day moving average price is $1.23 and its 200 day moving average price is $1.95. Rockwell Medical has a 52 week low of $0.86 and a 52 week high of $5.15.

Insider Buying and Selling at Rockwell Medical

In other news, major shareholder Larson Family Inve Irrevocable purchased 57,000 shares of Rockwell Medical stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.07 per share, for a total transaction of $60,990.00. Following the acquisition, the insider now directly owns 3,527,000 shares in the company, valued at $3,773,890. This represents a 1.64% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 10,680 shares of company stock worth $11,552. 3.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their target price on Rockwell Medical from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, March 24th.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.